Free Trial
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

Medifast logo
$14.71 +0.38 (+2.67%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$14.75 +0.04 (+0.25%)
As of 02/21/2025 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Medifast Stock (NYSE:MED)

Key Stats

Today's Range
$14.24
$14.94
50-Day Range
$14.34
$19.14
52-Week Range
$13.57
$42.68
Volume
329,782 shs
Average Volume
232,291 shs
Market Capitalization
$160.96 million
P/E Ratio
81.74
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Hold

Company Overview

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Medifast Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

MED MarketRank™: 

Medifast scored higher than 71% of companies evaluated by MarketBeat, and ranked 68th out of 151 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Medifast has only been the subject of 1 research reports in the past 90 days.

  • Read more about Medifast's stock forecast and price target.
  • Earnings Growth

    Earnings for Medifast are expected to grow by 200.00% in the coming year, from $0.51 to $1.53 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medifast is 81.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.58.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medifast is 81.74, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 16.38.

  • Price to Book Value per Share Ratio

    Medifast has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Medifast's valuation and earnings.
  • Percentage of Shares Shorted

    12.91% of the float of Medifast has been sold short.
  • Short Interest Ratio / Days to Cover

    Medifast has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Medifast has recently decreased by 2.14%, indicating that investor sentiment is improving.
  • Dividend Yield

    Medifast does not currently pay a dividend.

  • Dividend Growth

    Medifast does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.91% of the float of Medifast has been sold short.
  • Short Interest Ratio / Days to Cover

    Medifast has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Medifast has recently decreased by 2.14%, indicating that investor sentiment is improving.
  • News Sentiment

    Medifast has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Consumer Staples companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Medifast this week, compared to 3 articles on an average week.
  • Search Interest

    Only 4 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Medifast to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Medifast insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.50% of the stock of Medifast is held by insiders.

  • Percentage Held by Institutions

    95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Medifast's insider trading history.
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

MED Stock News Headlines

Medifast Full Year 2024 Earnings: EPS Beats Expectations
Q4 2024 Medifast Inc Earnings Call
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
Medifast sees Q1 revenue $100M-$120M
Medifast reports Q4 adjusted EPS 10c vs. $1.09 last year
Medifast Faces Revenue Challenges Amid New Product Launch
See More Headlines

MED Stock Analysis - Frequently Asked Questions

Medifast's stock was trading at $17.62 at the beginning of the year. Since then, MED stock has decreased by 16.5% and is now trading at $14.7130.
View the best growth stocks for 2025 here
.

Medifast, Inc. (NYSE:MED) announced its earnings results on Tuesday, February, 18th. The specialty retailer reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.26. The specialty retailer earned $119 million during the quarter, compared to analyst estimates of $114.25 million. Medifast had a trailing twelve-month return on equity of 10.64% and a net margin of 0.35%.

Medifast's top institutional shareholders include Renaissance Technologies LLC (8.26%), Federated Hermes Inc. (2.55%), Bank of America Corp DE (2.52%) and Geode Capital Management LLC (2.25%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist.
View institutional ownership trends
.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

Last Earnings
2/18/2025
Today
2/21/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
870
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.50
High Stock Price Target
$16.50
Low Stock Price Target
$16.50
Potential Upside/Downside
+12.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$99.42 million
Pretax Margin
0.63%

Debt

Sales & Book Value

Annual Sales
$602.46 million
Cash Flow
$3.02 per share
Book Value
$19.21 per share

Miscellaneous

Free Float
10,665,000
Market Cap
$160.96 million
Optionable
Optionable
Beta
1.14

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSE:MED) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners